Drugs

Umicore Argentina S.A.

FDA issued a warning letter to Umicore Argentina S.A. (Brussels, Belgium) on Nov 6, 2026. Subject: CGMP, Active Pharmaceutical Ingredient (API), Adulterated.

From the letter: “You failed to adequately investigate over 300 out-of-specification (OOS) results related to assay, related substances/impurities, microbiological monitoring, and water quality since 2021, of which more than 200 OOS results were invalidated.”

Brussels, BelgiumIssued Nov 6, 2026Posted Nov 17, 2026No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
15 findings · 2 issue types
Cited
No CFR or ISO section
Response due
Fifteen (15) business days of receipt
FDA asks for
8 actions
Named as possible actions
Seizure, injunction, refusal of admission
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Investigations & OOSOver 300 OOS results were inadequately investigated and more than 200 were invalidated without proper justification.
You failed to adequately investigate over 300 out-of-specification (OOS) results related to assay, related substances/impurities, microbiological monitoring, and water quality since 2021, of which more than 200 OOS results were invalidated.
02Investigations & OOSPhase II investigations were skipped or misattributed to analyst error when no laboratory cause was found.
when Phase I investigations found no conclusive laboratory error, Phase II investigations were either not conducted or improperly attributed the failing results to analyst or procedural error.
03Investigations & OOSOOS results were invalidated solely on passing reanalysis without adequate investigation.
The initial OOS results were then invalidated based solely on passing results after reanalysis.
04Investigations & OOSAnalyst retraining was uniformly applied as CAPA even when lab error was not the root cause.
Analyst retraining was uniformly applied as a corrective action, even when Phase I investigations confirmed that laboratory errors were not the root cause of the OOS.
05Investigations & OOSMicrobial OOS investigations lacked organism identification.
your investigations into API samples that exceeded the specification for total aerobic count did not include microbial identification.
06Investigations & OOSRecurring particulate complaints were not adequately investigated.
your firm failed to adequately investigate recurring complaints of foreign particulate matter in your (b)(4) batches.
07Investigations & OOSPotential root cause for particulate matter was not confirmed by analytical characterization.
you did not perform analytical characterization to confirm your potential root cause.
08Investigations & OOSNot all observed particle types were evaluated in the complaint investigation.
you failed to evaluate all observed particle types ((b)(4)) in your (b)(4) batches.
09Facilities & equipmentPeeling material was found on a product contact surface of a tank.
Peeling material on the product contact side of the (b)(4) on (b)(4) tank (b)(4).
10Facilities & equipmentUnidentified residues were found on tanks documented as clean.
Unidentified (b)(4) residues near the openings and (b)(4), and (b)(4) residues near the (b)(4), on (b)(4) tanks (b)(4), despite (b)(4) tanks being documented as “clean”.
11Facilities & equipmentStagnant water was found in a transfer line between tanks.
Stagnant water filling the transfer line between (b)(4) tanks (b)(4).
12Facilities & equipmentA flying insect was found in a tank.
A flying insect was observed at the bottom of the (b)(4) tank (b)(4).
13Facilities & equipmentCracked ceiling with debris above an open tank posed contamination risk.
A cracked and damaged ceiling above (b)(4) tank (b)(4), with (b)(4) particulate debris resting on top of the (b)(4) tank directly below.
14Facilities & equipmentLive insects were present in manufacturing and packaging areas.
Live insects on and around equipment and floors where (b)(4), and API packaging activities occur.
15Facilities & equipmentEquipment parts were stored in bins with standing water and particles.
(b)(4) stored (b)(4) and in bins containing standing water and (b)(4) particles.

Additional FDA passages

4 extracted findings

Selected FDA passages, not the complete letter.

01

Failure to adequately investigate and document out-of-specification results and implement appropriate corrective actions.

02

Failure to properly maintain equipment, buildings, and facilities used in the manufacture of API in a clean condition. You also failed to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the API beyond the official or other established specifications.

03

You failed to adequately maintain your equipment and facility in a good state of repair. For example, our investigators observed the following:

04

Failure to address any deviations may also result in the FDA refusing admission of articles manufactured at Umicore Argentina S.A. Buenos Aires into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).

What FDA requested

  • Independent retrospective review of all critical investigations for the last three years, evaluating adequacy of production review, related data, scope, rigor, competencies, root cause, and CAPA
  • Independent assessment and remediation plan for CAPA program, including root cause analysis, effectiveness, trend analysis, and executive support
  • Retrospective independent review of all invalidated OOS results for U.S. products for the last three years, with scientific justification and manufacturing root cause analysis
  • Comprehensive review and remediation plan for OOS investigation systems, including quality unit oversight, trend identification, and revised procedures
  • CAPA plan for routine oversight of facilities and equipment, including independent consultant and preventive maintenance
  • Comprehensive independent retrospective assessment of cleaning effectiveness, including residue identity and cross-contamination hazards
  • Procedure for water system monitoring with routine microbial testing
  • Current action/alert limits for total counts and objectionable organisms in water system, with justification for stringency

FDA Warning Letter

63 paragraphs · 6 sections

Text as published on FDA.gov, retrieved Nov 18, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

DatedNovember 6, 2026
Reference320-27-20
AddressedMr. Bart Sap

1Introduction

1 paragraph

This warning letter advises you of significant deviations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility and provides you an opportunity to address them. Promptly address any deviations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the deviations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any deviations may result in regulatory action without further notice including, without limitation, seizure and injunction.

2FDA Inspection

4 paragraphs

Deviations were observed and documented during an inspection of your drug manufacturing facility, Umicore Argentina S.A., FDA Establishment Identifier (FEI) 3009867894, at Calle 14 No. 229 Parque Industrial Pilar, Lote 13, Pilar, Buenos Aires, from June 4 to 9, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.

This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).

Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).

We reviewed your June 30, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.

3Violations of the Federal Food, Drug, and Cosmetic Act

1 paragraph

The following are deviations identified during our inspection and review. As a reminder, this is not an all-inclusive list of deviations at your facility.

41. Failure to adequately investigate and document out-of-specification results and implement appropriate corrective actions.

35 paragraphs

You manufacture APIs (e.g. (b)(4)) intended for use in (b)(4) drug products. You failed to adequately investigate over 300 out-of-specification (OOS) results related to assay, related substances/impurities, microbiological monitoring, and water quality since 2021, of which more than 200 OOS results were invalidated. Our investigators conducted a review of 30 OOS investigation records and found a consistent pattern: when Phase I investigations found no conclusive laboratory error, Phase II investigations were either not conducted or improperly attributed the failing results to analyst or procedural error. The initial OOS results were then invalidated based solely on passing results after reanalysis. Analyst retraining was uniformly applied as a corrective action, even when Phase I investigations confirmed that laboratory errors were not the root cause of the OOS. Your overreliance on human error as a root cause, particularly when no specific laboratory error is identified, is deficient. OOS laboratory results must be fully investigated, including the initiation of Phase II manufacturing investigations when appropriate.

Additionally, your investigations into API samples that exceeded the specification for total aerobic count did not include microbial identification. You acknowledged that you lack a process to investigate elevated microbial counts, including too numerous to count results obtained from the (b)(4) of (b)(4) water samples. The lack of colony characterization during microbial OOS investigations was previously cited in your 2018 inspection. Identification of organisms is a fundamental part of investigations into microbial excursions.

Further, your firm failed to adequately investigate recurring complaints of foreign particulate matter in your (b)(4) batches. You determined that the potential root cause of the particulate matter was (b)(4); however, you did not perform analytical characterization to confirm your potential root cause. Additionally, you failed to evaluate all observed particle types ((b)(4)) in your (b)(4) batches.

In your response, you acknowledge deficiencies in your investigations and commit to reevaluating the previously closed OOS and complaint investigations. You commit to performing a three-year retrospective OOS review, as well as to establish a microbial identification program. You also commit to determining whether your (b)(4) water test method needs to be revised.

Your response is inadequate. It lacks sufficient details regarding the preliminary assessment of reopened investigations and fails to implement appropriate interim controls for API batches potentially affected by improperly invalidated results.

Additionally, your risk assessment for distributed batches lacks evidence or data to support your conclusions. Your commitment to establishing a microbial identification program does not include criteria for when identification is required or interim controls during program development. Your response also lacks evidence that remediation measures have been implemented to ensure that suspected laboratory errors are scientifically justified and that manufacturing causes are thoroughly investigated when laboratory errors cannot be conclusively identified.

Inadequate investigations can lead to unidentified root causes, ineffective corrective action and preventive action (CAPA), and recurring problems that compromise your ability to manufacture safe and effective APIs.

In response to this letter, provide:

An independent, retrospective review of all critical investigations (including each in-process, release, and stability test specification failure) for the last three years as of the date of this letter. Evaluate the adequacy of each investigation, including, but not limited to:o Determine whether a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment/facilities, variability of raw materials, process capability, written procedures deviation history, complaint history, batch failure history) was conducted.o Assess sufficiency of review of related data and investigations to identify if there are potential systemic linkages.o Evaluate adequacy of scope, rigor, staff investigation competencies, subject matter expertise, scientific/analytical foundation, root cause determinations, and CAPA.o Summary of findings of the assessment, and associated detailed CAPA, for each of the above elements.

An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.

A retrospective, independent review of all invalidated OOS (including in-process and release/stability testing) results for U.S. products, irrespective of whether the batch was ultimately distributed in the United States, for the last three years from the initial date of inspection, and a report summarizing the findings of the analysis, including the following for each OOS:o Determine whether the scientific justification and evidence relating to the laboratory incident and OOS result conclusively or inconclusively demonstrates causative laboratory error.o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.o For all laboratory incident and OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment/facilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.

A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:o Quality unit oversight of laboratory investigationso Identification of adverse laboratory control trendso Resolution of causes of laboratory variationo Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identifiedo Adequately scoping of each investigation and its CAPAo Revised OOS investigation procedures with these and other remediations

For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https://www.fda.gov/media/158416/download. While this guidance addresses chemistry laboratory analyses, many of its principles are also relevant to investigating out-of-specification microbiological results and out-of-trend results.

A possible laboratory error is insufficient to close an investigation at Phase 1. Whenever an investigation lacks conclusive evidence of laboratory error, a thorough investigation of potential manufacturing causes must be performed.

2. Failure to properly maintain equipment, buildings, and facilities used in the manufacture of API in a clean condition. You also failed to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the API beyond the official or other established specifications.

You failed to adequately maintain your equipment and facility in a good state of repair. For example, our investigators observed the following:

Peeling material on the product contact side of the (b)(4) on (b)(4) tank (b)(4).

Unidentified (b)(4) residues near the openings and (b)(4), and (b)(4) residues near the (b)(4), on (b)(4) tanks (b)(4), despite (b)(4) tanks being documented as “clean”.

Stagnant water filling the transfer line between (b)(4) tanks (b)(4).

A flying insect was observed at the bottom of the (b)(4) tank (b)(4).

A cracked and damaged ceiling above (b)(4) tank (b)(4), with (b)(4) particulate debris resting on top of the (b)(4) tank directly below. These conditions pose a contamination risk as the tank is opened during manufacturing and cleaning operations.

Live insects on and around equipment and floors where (b)(4), and API packaging activities occur.

(b)(4) stored (b)(4) and in bins containing standing water and (b)(4) particles. These parts are used for (b)(4) API (b)(4) steps. Notably, you acknowledged that (b)(4) are not routinely sanitized, and that (b)(4) is replaced (b)(4).

(b)(4) water samples collected directly from (b)(4) without (b)(4) or (b)(4), which is not representative of actual use conditions.

In your response, you state that the peeling material observed on (b)(4) tank (b)(4) was excess construction base material. You attribute the (b)(4) residues observed in (b)(4) tanks (b)(4) to (b)(4) carryover, the brown residues to joint adhesive, and the stagnant water in the transfer line to inadequate slope. As a corrective action, you commit to revising the applicable cleaning procedures and state that the (b)(4) tanks and the transfer line were taken out of service, recleaned, and inspected. You acknowledge the ceiling damage above (b)(4) tank (b)(4), but conclude the contamination risk was low, citing adequate spatial separation between the ceiling and the tank lid and the absence of manufacturing operations. While you state that the contamination risk was low, the ceiling was repaired and the area was cleaned prior to resuming operations. Finally, you acknowledge pest control program deficiencies and commit to revising your procedure to include all ISO-classified manufacturing areas, sealing identified pest entry points, and establishing a formal pest sighting reporting system.

Your response is inadequate. It lacks supporting analytical data, appropriate controls, and retrospective impact assessments for previously manufactured batches. Your conclusion that the peeling material on (b)(4) tank (b)(4) is excess base material relies solely on your installation qualification report and is unsupported by analytical identification. You also fail to evaluate or provide a retrospective impact assessment to determine whether this material may have contaminated previous drug product batches. While you acknowledge that the transfer line was not designed to drain properly, you fail to explain how this equipment was repeatedly approved and released as “clean.” You also do not address whether your cleaning validations remain valid or if the lack of proper drainage may have an impact on API quality.

Additionally, you provide no microbiological characterization of the product contact surfaces of the (b)(4) water (b)(4), nor did you assess the risk of biofilm formation on prior batches. Your revised standard operating procedure requires “periodic sanitization” without defining frequency, intervals, or acceptance criteria necessary for a controlled and validated program.

Further, you did not identify the debris on top of (b)(4) tank (b)(4). You also did not evaluate the risk of particulate ingress during manufacturing or cleaning operations when the tank lid was open, nor did you provide a retrospective product impact assessment. Although you outline procedural updates to your pest control program, you fail to provide a robust, scientifically supported risk assessment to justify the disposition of API batches manufactured in areas during the period of uncontrolled pest activity.

Proper equipment cleaning and facility maintenance are critical to preventing microbial, particulate, and chemical contamination in injectable drug APIs. Your failure to address underlying equipment and facility maintenance issues is concerning, given the incidence of OOS results, complaints, and inadequate root-cause investigations at your facility.

In response to this letter, provide:

Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should incorporate oversight from a qualified independent consultant and ensure, among other things, prompt detection of equipment/facilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment/facility infrastructure, and improved systems for ongoing management review.

A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment of whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.

A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.

The current action/alert limits for total counts and objectionable organisms used for your (b)(4) water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.

A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets (b)(4) specifications and appropriate microbial limits.

5CGMP Consultant Recommended

2 paragraphs

Based upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.

Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.

6Conclusion

6 paragraphs

You are responsible for investigating and determining the root causes of any deviations and implementing corrective and preventative measures to ensure future and sustained compliance so that these deviations and any others do not occur.

FDA may withhold approval of new applications or supplements listing your firm as a manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.

Failure to address any deviations may also result in the FDA refusing admission of articles manufactured at Umicore Argentina S.A. Buenos Aires into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).

If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.

Response requested

Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter2. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your written response with FEI 3009867894 and ATTN: Jamie Dion in the subject line of the email.

FDA posts warning letters to www.FDA.gov.

Sincerely,/S/

Francis GodwinDirectorOffice of Manufacturing QualityOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration

cc: Registered U.S. AgentTim FeuersteinMidas Pharmaceuticals Inc.(b)(6)

________________

1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.

2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 10, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

This letter cites no 21 CFR section or ISO 13485 clause.

Issue types

Investigations & OOSAI-assigned issue type202letters8findings here
49 letters issued this year vs 35 by the same date last year · +40%

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
Brussels, Belgium
Letter posted date
Nov 17, 2026
Letter issue date
Nov 6, 2026
Addressed to
Chief Executive Officer
Inspection dates
Jun 4, 2026
Response window
Not verified in this snapshot. Consult the original letter.
Record length
2,783 words · 59 recorded redactions
Published status
No published close-out
FDA reference
320-27-20
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 19, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,711 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.